- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Germany Next Generation Sequencing Market by Product (Reagents, Kits, Platforms) Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application - Forecast to 2031
USD 1.96 BN
MARKET SIZE, 2031
CAGR 16.0%
(2026-2031)
250
REPORT PAGES
60
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Germany Next Generation Sequencing market, valued at USD 0.85 billion in 2025, stood at USD 0.93 billion in 2026 and is projected to advance at a resilient CAGR of 16.0% from 2026 to 2031, culminating in a forecasted valuation of USD 1.96 billion by the end of the period. Next-generation sequencing refers to high-throughput DNA sequencing technologies that are not based on Sanger sequencing. NGS primarily relies on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. These methods are designed to handle large amounts of genomic data and are used in various fields, including clinical diagnostics, drug discovery and development, and agriculture research.
KEY TAKEAWAYS
-
By Offering
By offering, the products segment is projected to reach USD 1,270.5 million by 2031, growing at a CAGR of 14.0% during the forecast period.
-
By Consumables
By consumables, sequencing kits and reagents are projected to register a CAGR of 14.9% during the forecast period.
-
Competitive Landscape
Illumina, Thermo Fisher Scientific, and QIAGEN were identified as leading players in the Germany Next-generation Sequencing market, given their strong market presence and extensive technology portfolios.
The next-generation sequencing market in Germany is growing quickly, driven by advances in sequencing technologies, rising demand for precision medicine, and decreasing costs of sequencing. Market growth is also supported by initiatives like the German Alliance for Precision Medicine and collaborations aimed at improving the country's genomic research capabilities across clinical diagnostics, oncology, and rare disease management.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The German next-generation sequencing market is currently experiencing a period of innovation and rapid adoption. Healthcare systems, research institutions, and diagnostic laboratories across Germany are seeing advancements in sequencing platform development and regulatory approval processes. This progress aligns with emerging trends in precision oncology, rare disease diagnostics, and personalized treatment strategies. In Germany, the use of long-read sequencing technologies, advanced bioinformatics tools, and integrated sequencing platforms is increasing among hospitals and genomic research centers. These technologies enable faster analysis of complex genetic variants, structural variations, and epigenetic modifications, leading to quicker diagnoses, reduced turnaround times, and support for precision medicine and targeted therapies. Government agencies and regulatory authorities are promoting local innovation, the development of companion diagnostics, and public-private research collaborations. These efforts help shorten approval times and encourage the adoption of clinically validated sequencing platforms tailored to the needs of the German patient population.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Technological advancements in sequencing platforms
-
Rising demand for precision medicine and personalized healthcare
RESTRAINTS
Impact
Level
-
High Capital Investment and Operational Costs
OPPORTUNITIES
Impact
Level
-
Expanding applications in clinical diagnostics
CHALLENGES
Impact
Level
-
Data management and storage complexity
-
Shortage of Skilled Bioinformatics Professionals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Continuous advancements in next-generation sequencing (NGS) technologies, including enhancements in sequencing speed, accuracy, and throughput, are driving the adoption of NGS across Germany. These technological improvements allow researchers and clinicians to analyze large genomic datasets more effectively, supporting applications in genomics research, precision medicine, and clinical diagnostics.
Implementing NGS technologies requires significant investment in advanced sequencing equipment, laboratory infrastructure, and data analysis tools. Additionally, the need for skilled personnel and bioinformatics expertise raises operational costs, which can restrict the use of NGS technologies in smaller research labs and healthcare facilities.
The growing adoption of next-generation sequencing (NGS) in clinical diagnostics is driving significant growth opportunities in the Germany NGS market. NGS is commonly used in applications such as oncology testing, rare disease detection, and genetic disorder screening, allowing for more accurate and comprehensive identification of disease-related genetic variations.
NGS technologies produce large amounts of genomic data that require sophisticated storage systems and powerful computational infrastructure for analysis. Managing, interpreting, and securely storing this huge volume of data remains a significant challenge for research institutions and clinical laboratories adopting NGS technologies in Germany.
GERMANY NEXT GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Collaboration with German research institutes and clinical laboratories participating in the German genome sequencing pilot program to scale sequencing operations and integrate NGS into routine clinical care | Accelerates adoption of precision medicine and genomic diagnostics, enabling broader clinical use of sequencing technologies in oncology and rare disease research |
|
|
Use of Illumina sequencing technologies in the “Beyond the Exome” genomics research project conducted by German research institutions to identify clinically relevant genetic variants beyond traditional exome sequencing | Improves the detection of disease-associated genetic variants, supporting advanced genomic research and expanding the diagnostic capabilities of NGS |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Germany next-generation sequencing market is a collaborative ecosystem where technology providers, diagnostic laboratories, research institutions, bioinformatics companies, and healthcare professionals work together to develop and implement sequencing solutions in healthcare and research. Key players in Germany supply various sequencing platforms, consumables, reagents, and bioinformatics tools. Contract research organizations, diagnostic service providers, and academic institutions support the preclinical and clinical validation stages, as well as the implementation process for these sequencing technologies. Ultimately, healthcare organizations and research centers in Germany utilize the developed sequencing solutions, benefiting from supportive funding mechanisms and regulatory frameworks.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The products segment led the market in 2025, with sequencing platforms, consumables, and bioinformatics tools forming the core of most genomic analysis workflows used daily in research and clinical settings. This is because of their reliability, high throughput capacity, and proven performance, making them preferred choices for oncology diagnostics, rare disease detection, and precision medicine applications.
Diagnostics comprised the largest segment of the Germany Next-generation Sequencing market. The rising use of genomic analysis in disease diagnosis and treatment decisions has pushed this segment to the forefront in the country. Factors such as increased focus on precision medicine, rising cancer rates, more patients with rare genetic disorders, and expanded use of companion diagnostics are fueling the demand for sequencing-based diagnostic tests, oncology panels, and genetic screening services.
REGION
Germany to be the fastest growing county.
Germany is enhancing its genomic research capabilities by focusing on building partnerships and securing funding from government agencies like the German Federal Ministry of Education and Research. This support greatly bolsters Germany's role as a major research hub in the European Next-generation Sequencing market. The demand for oncology diagnostics, rare disease detection, and precision medicine applications is growing, alongside the development of sequencing infrastructure and bioinformatics skills in Germany. Moreover, substantial investment in genomic research efforts, combined with a strong clinical research foundation, is helping accelerate the shift of sequencing technologies from research environments to clinical practice.
GERMANY NEXT GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
Illumina, recognized as a leading player in the Germany next-generation sequencing market, offers a diverse portfolio that includes sequencing platforms, consumables, and bioinformatics solutions for clinical and research applications. The company maintains a strong presence in Germany and collaborates with research institutions, diagnostic laboratories, and pharmaceutical companies. Another key player in the German market is Thermo Fisher Scientific, known as a leading provider. The company is strengthening its position by launching advanced sequencing systems, integrated workflows, and specialty reagents designed for use in oncology, infectious disease, and genetic disorder diagnostics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific (US)
- QIAGEN (Netherlands)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies, Inc. (US)
- Oxford Nanopore Technologies plc (UK)
- PacBio (US)
- Eurofins Scientific (Luxembourg)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 852.6 Million |
| Market Forecast in 2031 (Value) | USD 1,960.3 Million |
| Growth Rate | CAGR of 16.0% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | Germany |
| Parent & Related Segment Reports |
Next generation Sequencing Market North America Next Generation Sequencing Market Europe Next Generation Sequencing Market Asia Pacific Next Generation Sequencing Market Single-molecule Real-time (SMRT) Sequencing Market France Next Generation Sequencing Market UK Next-generation Sequencing Market South Korea Next-Generation Sequencing Market China Next Generation Sequencing Market Next Generation Sequencing Services Market |
WHAT IS IN IT FOR YOU: GERMANY NEXT GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Understanding demand patterns for Next-generation Sequencing technologies across German healthcare and research systems | Assessed sequencing technology usage trends across key German institutions, highlighting differences in adoption of short-read and long-read platforms across oncology, rare disease, infectious disease, and research applications | Helps clients align product portfolios with institution-specific demand drivers, funding availability, and application priorities |
| Identifying local service providers and technology partners | Mapped regional sequencing service providers, bioinformatics companies, and diagnostic laboratories across Germany, with insights into sequencing capacity, data analysis capabilities, and clinical validation expertise | Supports partnership strategies, reduces implementation complexity, improves access to local expertise, and accelerates market entry |
RECENT DEVELOPMENTS
- May 2025 : QIAGEN acquired Genoox, an AI-driven genomic analysis platform provider, to strengthen its bioinformatics portfolio for genetic testing and next-generation sequencing data interpretation. The acquisition enhances QIAGEN's capabilities in clinical genomics and precision medicine applications.
- March 2023 : Illumina launched its first product with Illumina Complete Long-read technology, targeting improved sequencing capabilities for complex genomic regions and structural variant detection.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING PLATFORMS
4.2.1.2
RISING DEMAND FOR PRECISION MEDICINE AND PERSONALIZED HEALTHCARE
4.2.1.3
EXPANSION OF NATIONAL GENOMICS AND PRECISION MEDICINE INITIATIVES
4.2.2
RESTRAINTS
4.2.2.1
HIGH CAPITAL INVESTMENT AND OPERATIONAL COSTS
4.2.3
OPPORTUNITIES
4.2.3.1
EXPANDING APPLICATIONS IN CLINICAL DIAGNOSTICS
4.2.4
CHALLENGES
4.2.4.1
DATA MANAGEMENT AND STORAGE COMPLEXITY
4.2.4.2
SHORTAGE OF SKILLED BIOINFORMATICS PROFESSIONALS
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GERMANY HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GERMANY BIOTECH INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE TREND OF NEXT-GENERATION SEQUENCING PRODUCTS, BY KEY PLAYER, 2023-2025
5.5.2
AVERAGE SELLING PRICE OF NEXT-GENERATION SEQUENCING PRODUCTS, BY SERVICE,
5.5.3
AVERAGE SELLING PRICE TREND OF NEXT-GENERATION SEQUENCING PRODUCTS, BY COUNTRY, 2023-2025
5.6
TRADE ANALYSIS (2021-2025)
5.6.1
EXPORT SCENARIO (HS CODE 3822.00 & 9027.00)
5.6.2
IMPORT SCENARIO (HS CODE 3822.00 & 9027.00)
5.7
KEY CONFERENCES & EVENTS, 2026-2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.10
CASE STUDY ANALYSIS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY TECHNOLOGIES
6.1.1
SEQUENCING BY SYNTHESIS
6.1.2
ION SEMICONDUCTOR SEQUENCING
6.1.3
NANOPORE SEQUENCING
6.1.4
SMRT SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
AUTOMATED SAMPLE PREPARATION SYSTEM
6.2.2
BIOINFORMATICS AND DATA ANALYSIS PLATFORM
6.2.3
CRISPR-BASED TARGETED SEQUENCING
6.2.4
MULTIPLEX PCR
6.3
ADJACENT TECHNOLOGIES
6.3.1
SINGLE-CELL SEQUENCING TECHNOLOGY
6.3.2
MULTIOMICS INTEGRATION
6.3.3
SPATIAL GENOMICS AND TRANSCRIPTOMICS
6.3.4
GENE EDITING TECHNOLOGIES
6.4
TECHNOLOGY ROADMAP
6.5
PATENT ANALYSIS
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/ GEN AI ON GERMANY NEXT-GENERATION SEQUENCING MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED NEXT-GENERATION SEQUENCING WORKFLOWS
6.7.3
CASE STUDIES OF AI IMPLEMENTATION
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SEQUENCING SOLUTIONS
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.2
SUSTAINABILITY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
INTRODUCTION
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2
BUYING CRITERIA
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
GERMANY NEXT-GENERATION SEQUENCING MARKET, BY OFFERING, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY OFFERINGS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
9.1
INTRODUCTION
9.2
PRODUCTS
9.3
SERVICES
10
GERMANY NEXT-GENERATION SEQUENCING PRODUCT MARKET, BY TYPE (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY PRODUCT TYPES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
10.1
CONSUMABLES
10.1.1
LIBRARY PREP KITS & REAGENTS
10.1.2
SEQUENCING KITS & REAGENTS
10.1.3
OTHER CONSUMABLES
10.2
PLATFORMS
10.2.1
SEQUENCING PLATFORMS
10.2.2
LIBRARY PREPARATION PLATFORMS
10.3
BIOINFORMATICS TOOLS
10.3.1
DATA ANALYSIS SOFTWARE & WORKBENCHES
10.3.2
DATA VISUALIZATION TOOLS
10.3.3
OTHER TOOLS
NOTE 1: OTHER CONSUMABLES FLOW CELLS & PLATES, ADAPTERS, AND INDEX.
NOTE 2: OTHER TOOLS INCLUDE DATA COLLECTION SOFTWARE, FRAGMENT ANALYSIS SOFTWARE, GENOME ANNOTATION TOOLS & CLOUD PLATFORM FOR STORAGE AND DATA ANALYSIS, WORKFLOW AUTOMATION TOOLS.
11
GERMANY NEXT-GENERATION SEQUENCING PLATFORM’S MARKET, BY TECHNOLOGY, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY TECHNOLOGIES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
11.1
INTRODUCTION
11.2
SEQUENCING BY SYNTHESIS
11.3
ION SEMICONDUCTOR SEQUENCING
11.4
SINGLE-MOLECULE REAL-TIME SEQUENCING
11.5
NANOPORE SEQUENCING
11.6
0THER SEQUENCING TECHNOLOGIES
NOTE 3: OTHER SEQUENCING TECHNOLOGIES INCLUDE CRISPR-BASED SEQUENCING, OPTICAL MAPPING, ISH SEQUENCING, DNA NANOBALL SEQUENCING, COMBINATORIAL PROBE ANCHOR SYNTHESIS (CPAS), AND TRUE SINGLE-MOLECULE SEQUENCING, AMONG OTHERS.
12
GERMANY NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY PRODUCT WORKFLOW STEPS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
12.1
INTRODUCTION
12.2
SAMPLE PREPARATION/PRE-SEQUENCING
12.3
SEQUENCING
12.4
DATA ANALYSIS
13
GERMANY NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DEMAND PATTERNS, MARKET POTENTIAL ACROSS CUSTOMERS
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.3
CLINICAL & DIAGNOSTICS LABORATORIES
13.4
ACADEMIC & RESEARCH INSTITUTES
13.5
CROS & CDMOS
14
GERMANY NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY SERVICE TYPES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
14.1
INTRODUCTION
14.2
PRESEQUENCING SERVICES
14.2.1
SAMPLE PREPARATION/ISOLATION
14.2.2
LIBRARY PREPARATION & TARGET ENRICHMENT
14.2.3
QUALITY CONTROL
14.3
SEQUENCING SERVICES
14.3.1
EXOME & TARGETED RESEQUENCING AND CUSTOM PANELS
14.3.2
RNA SEQUENCING
14.3.3
DE NOVO SEQUENCING
14.3.4
CHIP SEQUENCING
14.3.5
WHOLE GENOME SEQUENCING
14.3.6
METHYL SEQUENCING
14.3.7
OTHER SEQUENCING SERVICES
14.4
BIOINFORMATICS AND DATA ANALYSIS SERVICES
14.4.1
DATA ANALYSIS SERVICES
14.4.2
DATA VISUALIZATION AND INTERPRETATION
14.4.3
DATA STORAGE AND MANAGEMENT SERVICES
14.5
SERVICES FOR NGS PLATFORM
NOTE 4: OTHER SEQUENCING SERVICES INCLUDE AMPLICON SEQUENCING, DIGITAL KARYOTYPING, EPIGENOMIC SEQUENCING, MICROBIOME SEQUENCING, AND METAGENOMICS.
15
GERMANY NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY SERVICE WORKFLOW STEPS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
15.1
INTRODUCTION
15.2
PRE-SEQUENCING
15.3
SEQUENCING
15.4
DATA ANALYSIS
16
GERMANY NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DEMAND PATTERNS, MARKET POTENTIAL ACROSS CUSTOMERS
16.1
INTRODUCTION
16.2
HOSPITALS & CLINICAL LABORATORIES
16.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.4
ACADEMIC AND RESEARCH INSTITUTES
16.5
OTHER END USERS
NOTE 5: OTHER END USERS INCLUDE GOVERNMENT AND REGULATORY AGENCIES, ENVIRONMENTAL AND INDUSTRIAL ORGANIZATIONS, AND CONSUMER GENOMICS COMPANIES.
17
GERMANY NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, (MARKET SIZE, 2024 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY APPLICATIONS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
17.1
INTRODUCTION
17.2
DIAGNOSTIC APPLICATION
17.2.1
CANCER DIAGNOSTICS
17.2.2
INFECTIOUS DISEASE DIAGNOSTICS
17.2.3
REPRODUCTIVE HEALTH DIAGNOSTIC
17.2.4
OTHER DIAGNOSTICS APPLICATION
17.3
DRUG DISCOVERY & DEVELOPMENT
17.3.1
PHARMACOGENOMICS
17.3.2
OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
17.4
AGRICULTURE AND ANIMAL RESEARCH
17.5
OTHER APPLICATIONS
NOTE 6: OTHER DIAGNOSTICS APPLICATIONS INCLUDE RARE GENETIC AND COMPLEX DISEASES SUCH AS IMMUNOLOGICAL, METABOLIC, NEUROLOGICAL, AND CARDIOVASCULAR DISEASES.
NOTE 7: OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS INCLUDE BIOMARKER DISCOVERY, DRUG TARGET IDENTIFICATION/DRUG EFFECT, POLY PHARMACOLOGY, VACCINE AND BIOPHARMA DEVELOPMENT.
NOTE 8: OTHER APPLICATIONS INCLUDE SYNTHETIC BIOLOGY, MARINE RESEARCH AND RESEARCH IN BIOFUELS, FORENSICS, METAGENOMICS & MICROBIOME ANALYSIS, AND EVOLUTIONARY STUDIES.
18
COMPETITIVE LANDSCAPE
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
18.1
INTRODUCTION
18.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN
18.3
REVENUE ANALYSIS, 2021-2025
18.4
MARKET SHARE ANALYSIS,
18.5
BRAND COMPARISON
18.5.1
ILLUMINA, INC.
18.5.2
THERMO FISHER SCIENTIFIC INC.
18.5.3
QIAGEN
18.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
18.6.1
STARS
18.6.2
EMERGING LEADERS
18.6.3
PERVASIVE PLAYERS
18.6.4
PARTICIPANTS
18.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
18.6.5.1
COMPANY FOOTPRINT
18.6.5.2
OFFERING FOOTPRINT
18.6.5.3
TECHNOLOGY FOOTPRINT
18.6.5.4
APPLICATION FOOTPRINT
18.7
COMPANY EVALUATION MATRIX: START-UPS/SMES,
18.7.1
PROGRESSIVE COMPANIES
18.7.2
RESPONSIVE COMPANIES
18.7.3
DYNAMIC COMPANIES
18.7.4
STARTING BLOCKS
18.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
18.7.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
18.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
18.8
COMPANY VALUATION AND FINANCIAL METRICS
18.9
COMPETITIVE SCENARIO
18.9.1
PRODUCT/SERVICE LAUNCHES
18.9.2
DEALS
18.9.3
EXPANSIONS
19
COMPANY PROFILES*
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE GERMANY NEXT-GENERATION SEQUENCING MARKET LANDSCAPE
19.1
KEY PLAYERS
19.1.1
ILLUMINA, INC.
19.1.2
THERMO FISHER SCIENTIFIC INC.
19.1.3
QIAGEN
19.1.4
F. HOFFMANN-LA ROCHE LTD.
19.1.5
AGILENT TECHNOLOGIES, INC.
19.1.6
OXFORD NANOPORE TECHNOLOGIES
19.1.7
PACBIO
19.1.8
EUROFINS SCIENTIFIC
20
RESEARCH METHODOLOGY
20.1
RESEARCH DATA
20.1.1
SECONDARY DATA
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
20.1.2
PRIMARY DATA
20.1.2.1
KEY DATA FROM PRIMARY SOURCES
20.1.2.2
KEY PRIMARY PARTICIPANTS
20.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
20.1.2.4
KEY INDUSTRY INSIGHTS
20.2
MARKET SIZE ESTIMATION
20.2.1
GERMANY NEXT-GENERATION SEQUENCING MARKET ESTIMATION,
20.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
20.2.1.2
MNM REPOSITORY ANALYSIS
20.2.1.3
PRIMARY RESEARCH
20.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
20.3
MARKET GROWTH RATE PROJECTIONS
20.4
DATA TRIANGULATION
20.5
FACTOR ANALYSIS
20.6
RESEARCH ASSUMPTIONS
20.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
21
APPENDIX
21.1
DISCUSSION GUIDE
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
AVAILABLE CUSTOMIZATIONS
21.4
RELATED REPORTS
21.5
AUTHOR DETAILS
Methodology
This study on the Germany next Generation Sequencing Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the Germany next Generation Sequencing Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Germany next Generation Sequencing Market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Germany next Generation Sequencing Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Germany next Generation Sequencing Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies.
Report Objectives
- To define, describe, and forecast the Germany next Generation Sequencing Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall Germany next Generation Sequencing Market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Germany next Generation Sequencing Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the Germany next Generation Sequencing Market
- To benchmark players within the Germany next Generation Sequencing Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy.
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Germany Next Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Germany Next Generation Sequencing Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
